English Español
Donate
Back to Clinical Trials
Back to Clinical Trials

Brief Title: A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies

A Phase 1 Study to Evaluate the Safety and Tolerability of AB154 Monotherapy and Combination Therapy in Participants With Advanced Malignancies

INTRODUCTION

  • Org Study ID: AB154CSP0001
  • Secondary ID: N/A
  • NTC ID: NCT03628677
  • Sponsor: Arcus Biosciences, Inc.

BRIEF SUMMARY


This is a Phase 1, multicenter, open-label, dose-escalation study to evaluate the safety,
tolerability, PK, PD, and clinical activity of AB154 as monotherapy and in combination with
AB122 in participants with advanced solid malignancies.

DETAILED DESCRIPTION


This is a Phase 1, multicenter, open-label, dose-escalation study to evaluate the safety,
tolerability, PK, PD, and clinical activity of AB154 as monotherapy and in combination with
AB122 in participants with advanced solid malignancies. In this dose escalation study,
participants will receive AB154 administered intravenously as monotherapy or in combination
with AB122. Treatment will continue until progressive disease, unacceptable toxicity,
withdrawal of consent, or other reasons for study drug discontinuation occurs.


  • Overall Status
    Recruiting
  • Start Date
    August 21, 2018
  • Phase
    Phase 1
  • Study Type
    Interventional

PRIMARY OUTCOMES

Primary Outcome 1 - Measure: Number of Participants with Treatment Emergent Adverse Events (TEAEs) as Assessed by CTCAE v5.0

Primary Outcome 1 - Timeframe: From First Dose Date to 6 Months After Last Dose

CONDITION

  • Non-small Cell Lung Cancer
  • Squamous Cell Carcinoma of the Head and Neck
  • Renal Cell Carcinoma
  • Breast Cancer
  • Colorectal Cancer
  • Melanoma
  • Bladder Cancer
  • Ovarian Cancer
  • Endometrial Cancer
  • Merkel Cell Carcinoma
  • GastroEsophageal Cancer

ELIGIBILITY


Inclusion Criteria:

1. Capable of giving signed informed consent

2. Male or female participants ≥ 18 years of age at the time of screening

3. Negative serum pregnancy test at screening and prior to dosing on Cycle 1 Day 1;
negative serum or urine pregnancy test on the first day of each subsequent treatment
period

4. Pathologically confirmed non-small cell lung cancer, squamous cell carcinoma of the
head and neck, renal cell carcinoma, breast cancer, colorectal cancer, melanoma,
bladder cancer, ovarian cancer, endometrial cancer, Merkel cell carcinoma, or
gastroesophageal cancer that is metastatic, advanced, or recurrent with progression
for which no alternative or curative therapy exists or standard therapy is not
considered appropriate by the participant and treating physician

5. Must have at least 1 measurable lesion per Response Evaluation Criteria in Solid
Tumors (RECIST) v1.1. The measurable lesion must be outside of a radiation field if
the participant received prior radiation

6. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1

7. Must have received standard of care, including potentially curative available
therapies or interventions

8. Confirmation that an archival tissue sample is available and ≤ 6 months old; if not, a
new biopsy of a tumor must be obtained

9. Prior chemotherapy or immunotherapy (tumor vaccine, cytokine, or growth factor given
to control the cancer) or biologic agents must have been completed at least 4 weeks
before investigational product administration, and all AEs have either returned to
baseline or stabilized

10. Immunosuppressive doses of systemic medications, such as corticosteroids or absorbed
topical corticosteroids (doses > 10 mg/day prednisone or equivalent) must be
discontinued at least 2 weeks (14 days) before investigational product administration.
Physiologic doses of corticosteroids < 10 mg/day of prednisone or its equivalent may
be permitted

11. Prior surgery that required general anesthesia or other major surgery as defined by
the Investigator must be completed at least 4 weeks before investigational product
administration

12. Negative tests for hepatitis B surface antigen, hepatitis C virus antibody (or
hepatitis C qualitative ribonucleic acid [RNA; qualitative]), and human
immunodeficiency virus (HIV)-1 and HIV-2 antibody at screening

13. Adequate organ and marrow function

Exclusion Criteria:

1. Use of any live vaccines against infectious diseases (eg, influenza, varicella) within
4 weeks (28 days) of initiation of investigational product

2. Underlying medical conditions that, in the Investigator's or Sponsor's opinion, will
make the administration of investigational product hazardous (eg, interstitial lung
disease, active infections requiring antibiotics, recent hospitalization with
unresolved symptoms)

3. Has known psychiatric or substance abuse disorders that would interfere with
cooperation with the requirements of the trial

4. Any active autoimmune disease or a documented history of autoimmune disease or history
of a syndrome that required systemic steroids or immunosuppressive medications, except
for vitiligo or resolved childhood asthma/atopy. Participants with asthma who require
intermittent use of bronchodilators (such as albuterol) will not be excluded from this
study

5. Prior malignancy active within the previous year except for locally curable cancers
that have been apparently cured, such as basal or squamous cell skin cancer,
superficial bladder cancer, or carcinoma in situ of the cervix, breast, or prostate
cancer

Gender: All

Minimum Age: N/A

Maximum Age: 18 Years

Healthy Volunteers: No

OFFICIAL INFORMATION

Name: Medical Director

Role: Study Director

Affiliation: Arcus Biosciences, Inc.

Overall Contact

Name: Medical Director

Phone: 510-694-6200

Email: ClinicalTrialInquiry@arcusbio.com

LOCATION

Facility Status Contact
Facility: Principal Investigator
Los Angeles, California 90025
United States 		Status: Recruiting Contact:
Principal Investigator
Facility: Huntersville, NC
Huntersville, North Carolina 28078
United States 		Status: Recruiting Contact:
Principal Investigator
Facility: Principal Investigator
San Antonio, Texas 78229
United States 		Status: Recruiting Contact:
Principal Investigator
Facility: Spokane, WA
Spokane, Washington 99208
United States 		Status: Recruiting Contact:
Principal Investigator
Facility: Albury, Australia
Albury, New South Wales 2640
Australia 		Status: Recruiting Contact:
Principal Investigator
Facility: Darlinghurst, Australia
Darlinghurst, New South Wales 2010
Australia 		Status: Recruiting Contact:
Principal Investigator
Facility: Randwick, Australia
Randwick, New South Wales 2031
Australia 		Status: Recruiting Contact:
Principal Investigator
Facility: Principal Investigator
South Brisbane, Queensland 4101
Australia 		Status: Recruiting Contact:
Principal Investigator
Facility: Heidelberg, Australia
Heidelberg, Victoria 3084
Australia 		Status: Recruiting Contact:
Principal Investigator

Read Our Stories